Ilan Goldenberg
Concepts (443)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Defibrillators, Implantable | 33 | 2005 | 35 |
Why?
| Death, Sudden, Cardiac | 34 | 1993 | 31 |
Why?
| Long QT Syndrome | 26 | 2005 | 35 |
Why?
| Myocardial Infarction | 26 | 1989 | 129 |
Why?
| Heart Failure | 21 | 1986 | 106 |
Why?
| Cardiac Resynchronization Therapy | 9 | 2010 | 8 |
Why?
| Bezafibrate | 9 | 2004 | 1 |
Why?
| Electrocardiography | 31 | 1986 | 132 |
Why?
| Ventricular Dysfunction, Left | 13 | 2006 | 35 |
Why?
| Risk Assessment | 27 | 2003 | 324 |
Why?
| Arrhythmias, Cardiac | 10 | 1989 | 65 |
Why?
| Hypolipidemic Agents | 8 | 2004 | 17 |
Why?
| Heart Arrest | 14 | 1989 | 37 |
Why?
| Syncope | 18 | 1989 | 24 |
Why?
| Coronary Artery Disease | 9 | 1990 | 56 |
Why?
| Risk Factors | 42 | 1990 | 555 |
Why?
| Genetic Predisposition to Disease | 13 | 2005 | 131 |
Why?
| Female | 108 | 1973 | 1643 |
Why?
| Aged | 62 | 1973 | 988 |
Why?
| Adrenergic beta-Antagonists | 16 | 1989 | 47 |
Why?
| Male | 104 | 1986 | 1553 |
Why?
| Proportional Hazards Models | 25 | 2003 | 123 |
Why?
| Genotype | 18 | 2005 | 175 |
Why?
| Cholesterol, HDL | 4 | 2005 | 26 |
Why?
| Humans | 128 | 1973 | 1856 |
Why?
| Tachycardia, Ventricular | 7 | 2006 | 25 |
Why?
| Coronary Disease | 9 | 1989 | 94 |
Why?
| Middle Aged | 74 | 1973 | 1161 |
Why?
| Electric Countershock | 5 | 1990 | 24 |
Why?
| Contrast Media | 3 | 2004 | 116 |
Why?
| Follow-Up Studies | 26 | 1974 | 553 |
Why?
| Kaplan-Meier Estimate | 15 | 2007 | 89 |
Why?
| Jervell-Lange Nielsen Syndrome | 2 | 2006 | 5 |
Why?
| Prognosis | 17 | 1964 | 388 |
Why?
| Romano-Ward Syndrome | 4 | 2007 | 7 |
Why?
| Dyslipidemias | 2 | 2008 | 10 |
Why?
| Treatment Outcome | 22 | 1994 | 661 |
Why?
| Survival Rate | 14 | 1991 | 250 |
Why?
| KCNQ1 Potassium Channel | 7 | 2007 | 13 |
Why?
| Blood Pressure | 4 | 1989 | 205 |
Why?
| Acute Kidney Injury | 2 | 2004 | 34 |
Why?
| Polymorphism, Genetic | 2 | 2006 | 94 |
Why?
| Bundle-Branch Block | 6 | 2005 | 17 |
Why?
| Cardiovascular Diseases | 4 | 2006 | 127 |
Why?
| Recurrence | 15 | 1989 | 261 |
Why?
| Prospective Studies | 18 | 1974 | 545 |
Why?
| Heart Conduction System | 4 | 1989 | 37 |
Why?
| Ventricular Fibrillation | 6 | 1989 | 24 |
Why?
| Survival Analysis | 12 | 2006 | 205 |
Why?
| Ventricular Remodeling | 2 | 2011 | 21 |
Why?
| Glomerular Filtration Rate | 5 | 2006 | 33 |
Why?
| Phenotype | 11 | 2005 | 303 |
Why?
| European Continental Ancestry Group | 5 | 2006 | 117 |
Why?
| Smoking | 3 | 2004 | 153 |
Why?
| Mutation | 6 | 2007 | 340 |
Why?
| Coronary Angiography | 6 | 1989 | 49 |
Why?
| Heart Diseases | 3 | 1989 | 92 |
Why?
| Menopause | 3 | 1964 | 27 |
Why?
| Registries | 12 | 2006 | 83 |
Why?
| African Continental Ancestry Group | 3 | 2006 | 80 |
Why?
| Multivariate Analysis | 11 | 2003 | 225 |
Why?
| Age Distribution | 6 | 2007 | 127 |
Why?
| Myocardial Ischemia | 3 | 2003 | 62 |
Why?
| Acute Coronary Syndrome | 1 | 2010 | 4 |
Why?
| Kidney Failure, Chronic | 2 | 2007 | 57 |
Why?
| Time Factors | 18 | 1973 | 896 |
Why?
| Cardiovascular Agents | 1 | 2010 | 18 |
Why?
| Angioplasty, Balloon, Coronary | 6 | 1990 | 29 |
Why?
| Patient Selection | 2 | 2008 | 155 |
Why?
| Myocardium | 7 | 1987 | 119 |
Why?
| Adult | 43 | 1973 | 1317 |
Why?
| Incidence | 9 | 2004 | 336 |
Why?
| Renal Insufficiency | 2 | 2005 | 21 |
Why?
| Kidney Diseases | 2 | 2010 | 90 |
Why?
| Kidney | 2 | 2005 | 223 |
Why?
| Adolescent | 20 | 1986 | 891 |
Why?
| Age of Onset | 2 | 2007 | 64 |
Why?
| Heterozygote | 2 | 2007 | 80 |
Why?
| Renal Insufficiency, Chronic | 1 | 2008 | 9 |
Why?
| Child | 15 | 1986 | 749 |
Why?
| Cholesterol, LDL | 1 | 2008 | 23 |
Why?
| Decision Support Techniques | 1 | 2008 | 43 |
Why?
| Cholesterol Ester Transfer Proteins | 1 | 2007 | 9 |
Why?
| Health Care Costs | 2 | 2005 | 73 |
Why?
| Stroke Volume | 9 | 1986 | 54 |
Why?
| Angiotensinogen | 1 | 2006 | 8 |
Why?
| Myocardial Revascularization | 1 | 2006 | 18 |
Why?
| Child, Preschool | 11 | 1989 | 554 |
Why?
| Ether-A-Go-Go Potassium Channels | 3 | 2009 | 9 |
Why?
| Smoking Cessation | 2 | 2003 | 46 |
Why?
| Sex Distribution | 4 | 2007 | 101 |
Why?
| Models, Economic | 1 | 2005 | 14 |
Why?
| Cause of Death | 5 | 2006 | 82 |
Why?
| Infant | 10 | 1989 | 464 |
Why?
| Tissue Plasminogen Activator | 2 | 1989 | 31 |
Why?
| Young Adult | 8 | 2009 | 380 |
Why?
| Cardiomyopathy, Dilated | 7 | 1989 | 24 |
Why?
| Exercise | 4 | 1989 | 82 |
Why?
| Free Radical Scavengers | 1 | 2004 | 26 |
Why?
| Acetylcysteine | 1 | 2004 | 42 |
Why?
| Sodium Chloride | 1 | 2004 | 77 |
Why?
| Age Factors | 7 | 1974 | 480 |
Why?
| Heart | 2 | 1989 | 88 |
Why?
| Clinical Trials as Topic | 5 | 1989 | 251 |
Why?
| Adenosine | 1 | 2003 | 57 |
Why?
| Cardiac Pacing, Artificial | 3 | 2008 | 27 |
Why?
| Hypertension | 1 | 2006 | 161 |
Why?
| Cohort Studies | 9 | 1990 | 332 |
Why?
| Fibrinolytic Agents | 1 | 2003 | 42 |
Why?
| Angiotensin II | 1 | 2003 | 31 |
Why?
| Israel | 5 | 2003 | 20 |
Why?
| Risk | 5 | 1982 | 203 |
Why?
| Echocardiography, Doppler | 2 | 1991 | 20 |
Why?
| Mutation, Missense | 4 | 2007 | 59 |
Why?
| Stents | 2 | 2003 | 55 |
Why?
| Severity of Illness Index | 6 | 2007 | 358 |
Why?
| Retrospective Studies | 14 | 1986 | 653 |
Why?
| Ion Channel Gating | 2 | 2011 | 42 |
Why?
| Comorbidity | 3 | 2004 | 190 |
Why?
| Uric Acid | 2 | 2009 | 25 |
Why?
| Genetic Testing | 2 | 2008 | 49 |
Why?
| Ion Channels | 2 | 2008 | 61 |
Why?
| Aged, 80 and over | 10 | 1989 | 599 |
Why?
| Heart Valve Prosthesis | 3 | 1991 | 23 |
Why?
| Regression Analysis | 3 | 2007 | 256 |
Why?
| Chi-Square Distribution | 5 | 2006 | 179 |
Why?
| Predictive Value of Tests | 6 | 2005 | 321 |
Why?
| Exercise Test | 4 | 1993 | 51 |
Why?
| Hemodynamics | 7 | 1986 | 131 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 34 |
Why?
| Apoptosis | 1 | 2003 | 265 |
Why?
| Double-Blind Method | 3 | 1994 | 274 |
Why?
| Pacemaker, Artificial | 2 | 2008 | 29 |
Why?
| Triglycerides | 2 | 2005 | 48 |
Why?
| Statistics, Nonparametric | 3 | 2007 | 141 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2003 | 176 |
Why?
| Autoantibodies | 7 | 1989 | 64 |
Why?
| Diltiazem | 1 | 1994 | 15 |
Why?
| Atrial Flutter | 1 | 1994 | 11 |
Why?
| Coronary Artery Bypass | 3 | 1991 | 46 |
Why?
| Biological Markers | 4 | 2008 | 262 |
Why?
| Tachycardia | 2 | 1989 | 32 |
Why?
| Hospital Mortality | 4 | 2003 | 60 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2007 | 39 |
Why?
| Coronary Restenosis | 2 | 2002 | 7 |
Why?
| Diagnosis, Differential | 3 | 2010 | 402 |
Why?
| Atrial Fibrillation | 1 | 1994 | 40 |
Why?
| Sensitivity and Specificity | 3 | 1991 | 427 |
Why?
| Homocysteine | 2 | 2002 | 14 |
Why?
| Infant, Newborn | 4 | 2007 | 389 |
Why?
| Sequence Deletion | 2 | 2007 | 88 |
Why?
| Mitral Valve Insufficiency | 1 | 1991 | 19 |
Why?
| Sex Factors | 2 | 2010 | 284 |
Why?
| Estrogen Replacement Therapy | 1 | 2011 | 21 |
Why?
| Cardiac Resynchronization Therapy Devices | 1 | 2011 | 4 |
Why?
| Heart Failure, Systolic | 1 | 2010 | 1 |
Why?
| Reproducibility of Results | 2 | 2010 | 391 |
Why?
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2011 | 7 |
Why?
| Pregnancy Complications, Cardiovascular | 2 | 2007 | 28 |
Why?
| Myocardial Contraction | 1 | 2011 | 52 |
Why?
| United States | 6 | 2005 | 604 |
Why?
| Siblings | 1 | 2010 | 28 |
Why?
| Potassium | 2 | 1989 | 98 |
Why?
| Blood Urea Nitrogen | 1 | 2010 | 30 |
Why?
| Electrodes, Implanted | 1 | 2011 | 31 |
Why?
| Creatinine | 2 | 1974 | 69 |
Why?
| Blood Volume | 1 | 2010 | 35 |
Why?
| World Health | 1 | 2011 | 41 |
Why?
| Receptors, Adrenergic, beta | 4 | 1989 | 35 |
Why?
| Arousal | 1 | 2010 | 37 |
Why?
| Inpatients | 1 | 2010 | 46 |
Why?
| Creatine Kinase | 2 | 1986 | 37 |
Why?
| Echocardiography | 4 | 2011 | 93 |
Why?
| Hospitalization | 2 | 2008 | 169 |
Why?
| Tricuspid Valve Stenosis | 1 | 1989 | 2 |
Why?
| Cholesterol | 2 | 2004 | 86 |
Why?
| Electrocardiography, Ambulatory | 1 | 2010 | 23 |
Why?
| Receptors, Adrenergic | 1 | 1989 | 17 |
Why?
| Life Tables | 2 | 2004 | 33 |
Why?
| Dobutamine | 1 | 1989 | 19 |
Why?
| Heart Rate | 4 | 1989 | 138 |
Why?
| Balloon Dilation | 1 | 1989 | 42 |
Why?
| Sodium Channels | 1 | 2010 | 32 |
Why?
| Needs Assessment | 1 | 2010 | 67 |
Why?
| Body Mass Index | 1 | 2010 | 122 |
Why?
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 4 |
Why?
| Conserved Sequence | 1 | 2009 | 73 |
Why?
| Muscle Proteins | 1 | 2010 | 56 |
Why?
| Analysis of Variance | 2 | 2007 | 339 |
Why?
| Morbidity | 1 | 2008 | 62 |
Why?
| Diabetes Mellitus | 1 | 2009 | 72 |
Why?
| Asian Continental Ancestry Group | 1 | 2008 | 23 |
Why?
| Adrenergic beta-Agonists | 1 | 2008 | 39 |
Why?
| Hypotension | 4 | 1989 | 33 |
Why?
| Equipment Failure | 1 | 2008 | 44 |
Why?
| C-Reactive Protein | 1 | 2009 | 54 |
Why?
| Homozygote | 2 | 1995 | 68 |
Why?
| Confidence Intervals | 4 | 2007 | 104 |
Why?
| Cost-Benefit Analysis | 2 | 2005 | 118 |
Why?
| Genetic Variation | 1 | 2008 | 91 |
Why?
| Colonic Neoplasms | 1 | 2008 | 63 |
Why?
| African Americans | 1 | 2010 | 108 |
Why?
| Aryldialkylphosphatase | 1 | 2007 | 6 |
Why?
| Pregnancy, High-Risk | 1 | 2007 | 12 |
Why?
| Primary Prevention | 1 | 2008 | 44 |
Why?
| Lipids | 1 | 2007 | 97 |
Why?
| History, 20th Century | 1 | 2008 | 111 |
Why?
| Threonine | 1 | 2006 | 27 |
Why?
| Clofibric Acid | 1 | 2006 | 5 |
Why?
| Methionine | 1 | 2006 | 38 |
Why?
| Gene Frequency | 1 | 2006 | 42 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2007 | 31 |
Why?
| Breast Neoplasms | 6 | 1964 | 185 |
Why?
| Hypertriglyceridemia | 1 | 2006 | 14 |
Why?
| Equipment Design | 2 | 1989 | 132 |
Why?
| Electric Injuries | 1 | 1986 | 5 |
Why?
| Clinical Enzyme Tests | 1 | 1986 | 15 |
Why?
| Heart Injuries | 1 | 1986 | 14 |
Why?
| Pregnancy Outcome | 1 | 2007 | 54 |
Why?
| Hemorrhage | 2 | 1989 | 103 |
Why?
| Military Personnel | 2 | 2003 | 19 |
Why?
| Osmosis | 1 | 2005 | 14 |
Why?
| Mortality | 1 | 2006 | 50 |
Why?
| Serologic Tests | 1 | 2005 | 24 |
Why?
| Celiac Disease | 1 | 2005 | 11 |
Why?
| Outcome Assessment (Health Care) | 1 | 2008 | 163 |
Why?
| Platelet Aggregation Inhibitors | 2 | 1990 | 48 |
Why?
| Logistic Models | 2 | 2003 | 251 |
Why?
| Administration, Oral | 2 | 1973 | 170 |
Why?
| Ticlopidine | 1 | 2004 | 11 |
Why?
| Prodrugs | 1 | 2004 | 16 |
Why?
| Reference Values | 1 | 2006 | 278 |
Why?
| Asthma | 1 | 2008 | 97 |
Why?
| Glucose Intolerance | 1 | 2004 | 13 |
Why?
| DNA Damage | 1 | 2005 | 66 |
Why?
| Adenosine A3 Receptor Agonists | 1 | 2003 | 1 |
Why?
| Receptor, Adenosine A3 | 1 | 2003 | 2 |
Why?
| Adenosine A1 Receptor Agonists | 1 | 2003 | 5 |
Why?
| Receptor, Adenosine A1 | 1 | 2003 | 8 |
Why?
| Norepinephrine | 3 | 1987 | 68 |
Why?
| In Situ Nick-End Labeling | 1 | 2003 | 65 |
Why?
| Hematologic Tests | 1 | 2003 | 9 |
Why?
| Antioxidants | 1 | 2005 | 84 |
Why?
| Obesity | 1 | 2007 | 149 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 49 |
Why?
| Maternal Age | 1 | 1982 | 27 |
Why?
| Anemia | 1 | 2003 | 60 |
Why?
| Drug Administration Schedule | 1 | 2003 | 191 |
Why?
| Ventricular Function, Left | 3 | 1990 | 41 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1982 | 19 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2004 | 78 |
Why?
| Bradycardia | 3 | 1989 | 15 |
Why?
| Heart Catheterization | 4 | 1989 | 47 |
Why?
| Cardiopulmonary Bypass | 2 | 1990 | 22 |
Why?
| Cardiomyopathies | 2 | 2010 | 43 |
Why?
| Heart Ventricles | 3 | 1989 | 86 |
Why?
| Carcinoma | 1 | 1982 | 109 |
Why?
| Rats, Sprague-Dawley | 1 | 2003 | 257 |
Why?
| Disease Progression | 3 | 2004 | 244 |
Why?
| Coronary Vessels | 2 | 1989 | 53 |
Why?
| Health Surveys | 2 | 2010 | 103 |
Why?
| Canada | 2 | 2007 | 60 |
Why?
| Prevalence | 3 | 1993 | 281 |
Why?
| Heart Valve Diseases | 2 | 1994 | 18 |
Why?
| Transcription Factors | 1 | 2004 | 201 |
Why?
| Codon, Nonsense | 2 | 2007 | 15 |
Why?
| Coronary Thrombosis | 2 | 1990 | 9 |
Why?
| Membrane Potentials | 2 | 2007 | 99 |
Why?
| Heart Atria | 2 | 1989 | 37 |
Why?
| Combined Modality Therapy | 3 | 1990 | 219 |
Why?
| Posture | 4 | 1989 | 68 |
Why?
| Testolactone | 2 | 1973 | 1 |
Why?
| Probability | 2 | 2007 | 190 |
Why?
| Calcium | 1 | 2003 | 208 |
Why?
| Cells, Cultured | 1 | 2003 | 447 |
Why?
| Rats | 2 | 1991 | 530 |
Why?
| Models, Molecular | 2 | 2007 | 102 |
Why?
| HLA-DQ Antigens | 1 | 1995 | 6 |
Why?
| Isoproterenol | 3 | 1989 | 47 |
Why?
| Drug Therapy, Combination | 2 | 2004 | 189 |
Why?
| Prosthesis Design | 2 | 1991 | 44 |
Why?
| Genes, MHC Class II | 1 | 1995 | 17 |
Why?
| Receptors, Interleukin-2 | 1 | 1995 | 31 |
Why?
| Cardiac Tamponade | 1 | 1995 | 14 |
Why?
| Parity | 2 | 1982 | 28 |
Why?
| Injections, Intravenous | 1 | 1994 | 105 |
Why?
| Heart Transplantation | 3 | 1987 | 44 |
Why?
| Adenylate Cyclase | 2 | 1990 | 24 |
Why?
| Androstanes | 1 | 1973 | 1 |
Why?
| Pregnancy | 2 | 2007 | 455 |
Why?
| Cardiomyopathy, Hypertrophic | 1 | 1993 | 13 |
Why?
| Animals | 3 | 1991 | 1031 |
Why?
| Cardiac Output | 2 | 1986 | 48 |
Why?
| Mitral Valve | 1 | 1991 | 24 |
Why?
| Europe | 1 | 2011 | 54 |
Why?
| Cardiac Complexes, Premature | 1 | 2011 | 9 |
Why?
| Resuscitation | 1 | 1991 | 31 |
Why?
| Running | 1 | 2011 | 14 |
Why?
| Minnesota | 1 | 2010 | 22 |
Why?
| Physical Exertion | 1 | 2011 | 46 |
Why?
| Prosthesis Failure | 1 | 1991 | 38 |
Why?
| Ventricular Dysfunction, Right | 1 | 2010 | 11 |
Why?
| Electrophysiology | 1 | 2011 | 101 |
Why?
| Dose-Response Relationship, Drug | 3 | 1973 | 431 |
Why?
| Xenopus laevis | 1 | 2011 | 49 |
Why?
| Amiodarone | 1 | 1989 | 10 |
Why?
| Oocytes | 1 | 2011 | 45 |
Why?
| Postoperative Complications | 1 | 1995 | 305 |
Why?
| Fibrinolysis | 1 | 1989 | 17 |
Why?
| Carnitine | 1 | 1989 | 11 |
Why?
| Pulmonary Wedge Pressure | 1 | 1989 | 9 |
Why?
| Heart Septum | 1 | 1989 | 14 |
Why?
| Obesity, Morbid | 1 | 2010 | 28 |
Why?
| Protein Structure, Secondary | 1 | 2009 | 54 |
Why?
| Papillary Muscles | 1 | 1989 | 14 |
Why?
| Catheterization, Swan-Ganz | 1 | 1989 | 6 |
Why?
| Endpoint Determination | 1 | 2009 | 27 |
Why?
| Computer Simulation | 1 | 2011 | 134 |
Why?
| Thrombolytic Therapy | 1 | 1989 | 42 |
Why?
| Pulmonary Artery | 1 | 1989 | 58 |
Why?
| Embolization, Therapeutic | 1 | 1989 | 37 |
Why?
| Multicenter Studies as Topic | 1 | 2008 | 70 |
Why?
| Computational Biology | 1 | 2009 | 39 |
Why?
| Frameshift Mutation | 1 | 2007 | 20 |
Why?
| RNA Splice Sites | 1 | 2007 | 14 |
Why?
| Japan | 1 | 2007 | 25 |
Why?
| Netherlands | 1 | 2007 | 16 |
Why?
| Peptides | 2 | 1992 | 154 |
Why?
| Mutagenesis, Insertional | 1 | 2007 | 37 |
Why?
| Point Mutation | 1 | 2008 | 122 |
Why?
| Ion Transport | 1 | 2007 | 42 |
Why?
| Ligands | 1 | 2008 | 116 |
Why?
| Postpartum Period | 1 | 2007 | 32 |
Why?
| Aspartic Acid | 1 | 2007 | 37 |
Why?
| Isoenzymes | 2 | 1986 | 144 |
Why?
| Arginine Vasopressin | 1 | 1986 | 21 |
Why?
| Glutamine | 1 | 2007 | 27 |
Why?
| Cell Membrane | 1 | 1989 | 170 |
Why?
| Longitudinal Studies | 1 | 2008 | 195 |
Why?
| Protein Transport | 1 | 2007 | 101 |
Why?
| Arginine | 1 | 2007 | 57 |
Why?
| Castration | 2 | 1964 | 16 |
Why?
| Glutamic Acid | 1 | 2007 | 66 |
Why?
| Gestational Age | 1 | 2007 | 114 |
Why?
| L-Lactate Dehydrogenase | 1 | 1986 | 59 |
Why?
| Dopamine | 1 | 1987 | 62 |
Why?
| Gliadin | 1 | 2005 | 2 |
Why?
| Models, Biological | 1 | 2011 | 410 |
Why?
| Survivors | 1 | 2006 | 45 |
Why?
| Ovary | 2 | 1964 | 50 |
Why?
| Protein Structure, Tertiary | 1 | 2007 | 163 |
Why?
| New York | 1 | 2009 | 422 |
Why?
| Costs and Cost Analysis | 1 | 2005 | 71 |
Why?
| Amino Acid Sequence | 1 | 2009 | 319 |
Why?
| Immunoglobulin A | 1 | 2005 | 39 |
Why?
| Hematocrit | 2 | 1974 | 60 |
Why?
| Muscles | 1 | 1986 | 111 |
Why?
| Purinergic P2 Receptor Antagonists | 1 | 2004 | 8 |
Why?
| Platelet Aggregation | 1 | 2004 | 33 |
Why?
| Transglutaminases | 1 | 2005 | 12 |
Why?
| Biotransformation | 1 | 2004 | 25 |
Why?
| Adenosine Diphosphate | 1 | 2004 | 30 |
Why?
| Epinephrine | 1 | 2004 | 53 |
Why?
| Aspirin | 1 | 2004 | 50 |
Why?
| Drug Resistance | 1 | 2004 | 83 |
Why?
| Hypercholesterolemia | 1 | 2004 | 33 |
Why?
| Naval Medicine | 1 | 2003 | 1 |
Why?
| Submarine Medicine | 1 | 2003 | 2 |
Why?
| Erythrocyte Indices | 1 | 2003 | 5 |
Why?
| Testosterone | 1 | 1964 | 57 |
Why?
| Erythrocyte Count | 1 | 2003 | 18 |
Why?
| Molecular Sequence Data | 1 | 2009 | 404 |
Why?
| ROC Curve | 1 | 2003 | 80 |
Why?
| Physical Fitness | 1 | 2003 | 18 |
Why?
| Hemoglobins | 1 | 2003 | 74 |
Why?
| Biomedical Research | 1 | 1964 | 87 |
Why?
| Menarche | 1 | 1982 | 3 |
Why?
| Immunoglobulin G | 1 | 2005 | 191 |
Why?
| Mass Screening | 1 | 2005 | 125 |
Why?
| Blood Glucose | 1 | 2004 | 99 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 33 |
Why?
| Statistics as Topic | 1 | 2002 | 133 |
Why?
| Algorithms | 1 | 2005 | 226 |
Why?
| Body Weight | 1 | 1982 | 178 |
Why?
| Insulin | 1 | 2004 | 129 |
Why?
| Neoplasm Metastasis | 3 | 1964 | 112 |
Why?
| Emergencies | 2 | 1989 | 57 |
Why?
| Catecholamines | 2 | 1989 | 40 |
Why?
| Remission, Spontaneous | 2 | 1973 | 32 |
Why?
| Neoplasms | 1 | 1964 | 239 |
Why?
| Evaluation Studies as Topic | 2 | 1973 | 178 |
Why?
| HLA-DQ alpha-Chains | 1 | 1995 | 1 |
Why?
| HLA-DQ beta-Chains | 1 | 1995 | 2 |
Why?
| Haplotypes | 1 | 1995 | 28 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1995 | 18 |
Why?
| Histidine | 1 | 1995 | 42 |
Why?
| Disease Susceptibility | 1 | 1995 | 61 |
Why?
| Leucine | 1 | 1995 | 53 |
Why?
| Myosins | 1 | 1995 | 16 |
Why?
| Body Surface Area | 1 | 1994 | 8 |
Why?
| Alleles | 1 | 1995 | 108 |
Why?
| Aortic Valve | 1 | 1994 | 19 |
Why?
| Blood Flow Velocity | 1 | 1995 | 72 |
Why?
| Reoperation | 1 | 1995 | 106 |
Why?
| Ultrasonography, Doppler, Color | 1 | 1995 | 27 |
Why?
| Thallium Radioisotopes | 1 | 1993 | 12 |
Why?
| Selection Bias | 1 | 1993 | 16 |
Why?
| Heart Function Tests | 1 | 1993 | 14 |
Why?
| Ketosteroids | 1 | 1973 | 1 |
Why?
| Vibration | 1 | 1993 | 26 |
Why?
| Radioligand Assay | 1 | 1992 | 30 |
Why?
| Neoplasm Recurrence, Local | 1 | 1974 | 118 |
Why?
| HLA-DR4 Antigen | 1 | 1990 | 2 |
Why?
| Dihydroalprenolol | 1 | 1990 | 4 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 224 |
Why?
| Base Sequence | 1 | 1995 | 371 |
Why?
| HLA Antigens | 1 | 1990 | 38 |
Why?
| Sodium Fluoride | 1 | 1990 | 16 |
Why?
| Reflex, Abnormal | 1 | 1989 | 13 |
Why?
| Vagus Nerve | 1 | 1989 | 25 |
Why?
| Clinical Protocols | 1 | 1989 | 93 |
Why?
| Infusions, Intravenous | 1 | 1989 | 87 |
Why?
| Binding Sites | 1 | 1991 | 213 |
Why?
| Electroencephalography | 1 | 1989 | 88 |
Why?
| Heparin | 1 | 1990 | 87 |
Why?
| Liver | 1 | 1973 | 248 |
Why?
| Vascular Resistance | 1 | 1986 | 51 |
Why?
| Mechlorethamine | 1 | 1964 | 7 |
Why?
| Pleural Effusion | 1 | 1964 | 24 |
Why?
| Drainage | 1 | 1964 | 50 |
Why?
| Pleural Neoplasms | 1 | 1964 | 18 |
Why?
| Toxicology | 1 | 1964 | 26 |
Why?
| Ovarian Neoplasms | 1 | 1964 | 64 |
Why?
| Lymphoma | 1 | 1964 | 96 |
Why?
| Lung Neoplasms | 1 | 1964 | 159 |
Why?
| 17-Ketosteroids | 1 | 1974 | 7 |
Why?
| Mastectomy | 1 | 1974 | 26 |
Why?
| Estrogens | 1 | 1974 | 45 |
Why?
| Lymphatic Metastasis | 1 | 1974 | 77 |
Why?
| Blood Vessels | 1 | 1974 | 65 |
Why?
| Glucocorticoids | 1 | 1974 | 107 |
Why?
| Lymph Nodes | 1 | 1974 | 106 |
Why?
| Palliative Care | 1 | 1974 | 65 |
Why?
|
|
Goldenberg's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
